Molbio Diagnostics IPO: Price Band, Lot Size, Financials & Review
Molbio Diagnostics IPO listed on BSE & NSE on Mon, 17 Aug 2026. The issue was subscribed 70.26x overall.
- Open Date
- 10 Aug 2026
- Close Date
- 12 Aug 2026
Last updated
- Price band
- ₹768 – ₹807
- Lot size
- 18 shares
- Min. investment
- ₹14,526
- Issue size
- ₹939.7 Cr
- Last GMP
- +₹126
- Subscribed
- 🔥 70.26x
Molbio Diagnostics IPO details
Molbio Diagnostics IPO is a ₹939.7 Cr book-building IPO on the Mainboard segment, listing on BSE & NSE. It combines a fresh issue of ₹200 Cr (21.28%) with an offer for sale of ₹739.7 Cr (78.72%) by existing shareholders. Only the fresh issue money goes to the company.
The issue was open from Mon, 10 Aug 2026 to Wed, 12 Aug 2026. Allotment was finalised on Thu, 13 Aug 2026, and the shares listed on BSE & NSE on Mon, 17 Aug 2026.
The price band is ₹768 to ₹807 per share and the lot size is 18 shares, so the minimum retail application is ₹14,526. Retail investors can apply for up to 13 lots (234 shares, ₹1,88,838).
KFin Technologies Limited is the registrar, and IIFL Capital Services Limited, Motilal Oswal Investment Advisors Ltd, Jefferies India Private Limited and Kotak Mahindra Capital Company Limited are the book running lead managers.
Grey market premium (GMP)
Day-wise GMP →The last Molbio Diagnostics IPO GMP before listing was +₹126 (+15.61% against the upper price band of ₹807), implying an estimated listing price of ₹933. Across 10 days of tracking, GMP ranged from 0 (04 Aug) to +₹180 (07 Aug).
| Last GMP | +₹126 |
|---|---|
| GMP vs upper band | +15.61% |
| Estimated listing price | ₹933 |
| Highest (07 Aug) | +₹180 |
| Lowest (04 Aug) | 0 |
Grey market trading is unofficial and unregulated. GMP is a sentiment indicator, not a guarantee of the listing price. See the Molbio Diagnostics IPO day-wise GMP.
Subscription
Day-wise subscription →Molbio Diagnostics IPO was subscribed 70.26x overall: QIB 186.39x, NII 49.80x and retail 12.96x.
| Category | Subscribed |
|---|---|
| QIB | 186.39x |
| NII | 49.80x |
| └ bNII (above ₹10 lakh) | 50.82x |
| └ sNII (₹2–10 lakh) | 47.76x |
| Retail | 12.96x |
| Employees | 13.28x |
| Total | 70.26x |
Final figures at the close of bidding on 12 Aug 2026. Category-wise bids, application-wise breakup and allotment chances are on the Molbio Diagnostics IPO day-wise and category-wise subscription page.
Share reservation by category
| Category | Shares offered | Share of issue |
|---|---|---|
| Anchor Investors | 34,87,717 | 29.95% |
| Qualified Institutions | 23,25,146 | 19.96% |
| Non-Institutional | 17,43,859 | 14.97% |
| └ BNII | 11,62,573 | 9.98% |
| └ SNII | 5,81,286 | 4.99% |
| Retail Investors | 40,69,004 | 34.94% |
| Employees | 20,520 | 0.18% |
| Total | 1,16,46,246 | 100.00% |
Shares offered include the anchor investor portion, which is allotted a day before the issue opens. Subscription figures exclude anchors, so category sizes on the subscription page are smaller.
Molbio Diagnostics IPO lot size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 18 | ₹14,526 |
| Retail (Max) | 13 | 234 | ₹1,88,838 |
| S-HNI (Min) | 14 | 252 | ₹2,03,364 |
| S-HNI (Max) | 68 | 1,224 | ₹9,87,768 |
| B-HNI (Min) | 69 | 1,242 | ₹10,02,294 |
Amounts at the upper end of the price band.
Issue structure and valuation
It combines a fresh issue of ₹200 Cr (21.28%) with an offer for sale of ₹739.7 Cr (78.72%) by existing shareholders. Only the fresh issue money goes to the company.
At the upper price band of ₹807, the issue is priced at 55.43x pre-issue earnings and 56.67x post-issue earnings per share.
The post-issue P/E is higher because the fresh issue adds new shares, which spreads the same profit over more shares.
Listed peers with positive earnings trade at a median P/E of 62.96x (4 companies).
Promoter holding falls from 46.65% before the issue to 43.01% after it.
| EPS (pre-issue) Latest earnings per share before the issue | ₹14.56 |
|---|---|
| P/E (pre-issue) Upper price band ÷ pre-issue EPS | 55.43x |
| EPS (post-issue) EPS on the enlarged share capital | ₹14.24 |
| P/E (post-issue) Upper price band ÷ post-issue EPS | 56.67x |
| Promoter holding (pre-issue) | 46.65% |
| Promoter holding (post-issue) | 43.01% |
Molbio Diagnostics Limited financials
Between 31 Mar 2025 and 31 Mar 2026, Income rose from ₹1,027.94 Cr to ₹1,455.17 Cr, and profit after tax rose from ₹138.58 Cr to ₹164.14 Cr. The PAT margin for 31 Mar 2026 was 11.28%.
| Period ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Total Income | 1,455.17 | 1,027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| Net Worth | 1,144.68 | 952.95 | 807.94 |
| Reserve & Surplus | 1,148.84 | 990.84 | 845.48 |
| Total Borrowings | 412.64 | 123.16 | 174.58 |
₹ in crore, as stated in the prospectus.
Key performance indicators
| KPI | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| ROE % | 15.59 | 16.20 | 13.20 |
| ROCE % | 17.55 | 20.98 | 15.80 |
| RoNW % | 14.55 | 15.23 | 12.62 |
| Pat Margin % | 11.28 | 13.48 | 9.94 |
Peer comparison
| Company | Face value | P/E | EPS (basic) | EPS (diluted) | RoNW | NAV |
|---|---|---|---|---|---|---|
| Molbio Diagnostics Ltd | 1 | — | 14.77 | 14.77 | 14.55% | 101.51 |
| Poly Medicure Ltd | 5 | 52.61 | 31.79 | 31.75 | 10.37% | 306.45 |
| Dr. Lal Pathlabs Ltd | 10 | 62.20 | 30.24 | 30.20 | 20.78% | 145.00 |
| Metropolis Healthcare Ltd | 2 | 63.72 | 9.19 | 9.19 | 12.56% | 72.98 |
| Vijaya Diagnostic Centre Ltd | 1 | 81.02 | 16.81 | 16.79 | 18.07% | 93.02 |
From the prospectus. P/E is shown as — when earnings are zero or negative, or not reported for the issuer before listing.
Objectives
The company intends to allocate the net proceeds from the offering to the following objectives.
| Sr | Objective |
|---|---|
| 1 |
About Molbio Diagnostics Limited
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of innovative rapid diagnostic solutions for infectious and non-communicable diseases.
The company has developed its proprietary Truenat platform, a portable, battery-operated, PCR-based molecular diagnostics system specifically designed for resource-limited settings. The platform delivers highly accurate molecular test results within approximately one hour, enabling timely diagnosis and treatment at the point of care.
Molbio offers a comprehensive portfolio of molecular diagnostic solutions covering more than 30 diseases through 43 diagnostic assays. Its product portfolio includes tests for tuberculosis (TB), COVID-19, HIV, Hepatitis B, Hepatitis C, Human Papillomavirus (HPV), and several other infectious diseases. In addition to molecular diagnostics, the company provides advanced healthcare solutions in radiology, digital pathology, and breast health screening through its subsidiaries and strategic partnerships. Molbio continues to strengthen its product pipeline through significant investments in in-house research and development.
The company operates six state-of-the-art manufacturing facilities across India and serves customers in more than 90 countries. Its diverse customer base includes government healthcare programs, public and private hospitals, diagnostic laboratories, research institutions, and international healthcare organizations. Supported by a robust intellectual property portfolio, global quality certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in the molecular diagnostics industry.
As of March 31, 2026, Molbio Diagnostics Limited employed 1,225 permanent employees across various functions, including research and development, manufacturing, quality assurance, regulatory affairs, sales and marketing, finance, information technology, and corporate operations.
Promoters
- Chandrasekhar Bhaskaran Nair
- Exxora Trading LLP
- Sangeetha Sriram
- Shiva Sriram
- Sowmya Sriram
- Sriram Natarajan
Contact details
Molbio Diagnostics Limited
Plot No. L-46
Phase II-D, Verna Industrial Area
Verna, Salcete South Goa, Goa, 403722
Telephone: +91 832 672488
Email: investors@molbiodiagnostics.com
Website: https://www.molbiodiagnostics.com/
Molbio Diagnostics IPO FAQs
- What is the Molbio Diagnostics IPO price band?
- The Molbio Diagnostics IPO price band is ₹768 to ₹807 per share.
- What is the Molbio Diagnostics IPO lot size and minimum investment?
- The Molbio Diagnostics IPO lot size is 18 shares. The minimum retail investment is ₹14,526 for one lot at the upper price band. Retail investors can apply for up to 13 lots (234 shares), costing ₹1,88,838.
- When was Molbio Diagnostics IPO open for subscription?
- Molbio Diagnostics IPO was open for subscription from Mon, 10 Aug 2026 to Wed, 12 Aug 2026.
- What is the Molbio Diagnostics IPO subscription status?
- Molbio Diagnostics IPO was subscribed 70.26x overall: QIB 186.39x, NII 49.80x and retail 12.96x. Day-wise and category-wise figures are on the subscription page.
- What was the Molbio Diagnostics IPO GMP before listing?
- The last Molbio Diagnostics IPO GMP before listing was +₹126 (+15.61% against the upper price band of ₹807), implying an estimated listing price of ₹933. Across 10 days of tracking, GMP ranged from 0 (04 Aug) to +₹180 (07 Aug). GMP is an unofficial grey market indicator and can change quickly.
- What is the Molbio Diagnostics IPO allotment date?
- The Molbio Diagnostics IPO basis of allotment was finalised on Thu, 13 Aug 2026. You can check your allotment status on the KFin Technologies Limited website.
- What is the Molbio Diagnostics IPO listing date?
- Molbio Diagnostics IPO listed on BSE & NSE on Mon, 17 Aug 2026.
- Is the Molbio Diagnostics IPO a fresh issue or an offer for sale?
- It combines a fresh issue of ₹200 Cr (21.28%) with an offer for sale of ₹739.7 Cr (78.72%) by existing shareholders. Only the fresh issue money goes to the company.
- Who are the registrar and lead managers of the Molbio Diagnostics IPO?
- The registrar for the Molbio Diagnostics IPO is KFin Technologies Limited, and the book running lead managers are IIFL Capital Services Limited, Motilal Oswal Investment Advisors Ltd, Jefferies India Private Limited and Kotak Mahindra Capital Company Limited.
Data is compiled from the prospectus, stock exchanges and market sources and is for information only. It is not investment advice; read the RHP before applying.